The cost-effectiveness of treatment for high-risk, early-stage, triple-negative breast cancer in Egypt: an analysis of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant single-agent pembrolizumab
In Egypt, pembrolizumab + chemotherapy/pembrolizumab is a cost-effective treatment for high-risk, early-stage, triple-negative breast cancer when considering health-related quality-of-life and years of life gained.
Authors
- Min Huang (ORCID: https://orcid.org/0000-0002-4362-0467)
- A.H. Abdelaziz (ORCID: https://orcid.org/0000-0002-3162-1825)
- Burak Ersoy (ORCID: https://orcid.org/0000-0001-8054-7740)
- Amin Haiderali (ORCID: https://orcid.org/0000-0002-6858-1564)
- Gihan Hamdy Elsisi (ORCID: https://orcid.org/0000-0002-2917-9388)
- Bernadette Poellinger (ORCID: https://orcid.org/0009-0008-3495-3930)
- Loay Kassem (ORCID: https://orcid.org/0000-0001-6559-5867)
Institutions
- Ain Shams University (EG)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Cairo University (EG)
- American University (US)
- Health Economics and Outcomes Research (United Kingdom) (GB)
- Office of the Director (US)
- American University in Cairo (EG)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2024-12-12
- DOI
- https://doi.org/10.1080/13696998.2024.2441073
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.57